Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Adam Sperling, MD, PhD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, about the rationale to evaluate cellular therapy in multiple myeloma.
Sperling discussed how the disease biology of multiple myeloma has demonstrated clear involvement with the immune system, and immune escape is an important feature of the malignancy. As such, immune- and cellular-based therapies have been a cornerstone of treatment in this setting, Sperling adds.
In addition, myeloma plasma cells express BCMA almost universally, Sperling says. Moreover, BCMA is not present on normal cells, making it an optimal target for therapies, Sperling concludes.
The CAR-T Versus Bispecific Antibody Debate in Third Line LBCL
April 26th 2024Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin, discussed the advantages of each of the 2 modalities in the third and second line settings.
